title: Review article: cardiac adverse effects of gastrointestinal prokinetics.
abstract: Gastrointestinal prokinetics, such as metoclopramide, cisapride and levosulpiride, are widely used for the management of functional gut disorders. Recently, several studies have shown that cisapride (a partial 5-HT4 receptor agonist) can induce dose-dependent cardiac adverse effects, including lengthening of the electrocardiographic QT interval, syncopal episodes and ventricular dysrhythmias. Until recently, it was not clear whether these effects were dependent on 5-HT4 receptor activation or related to peculiar characteristics in the molecular structure of single agents within the benzamide class. Experimental evidence now favours the second hypothesis: cisapride possesses Class III antiarrhythmic properties and prolongs the action potential duration through blockade of distinct voltage-dependent K+ channels, thus delaying cardiac repolarization and prolonging the QT interval. Patients at risk of cardiac adverse effects are children, subjects with idiopathic, congenital or acquired long QT syndrome and, in particular, those receiving concomitant medication with Class III antiarrhythmic agents, some H1-receptor antagonists (e.g. terfenadine), or drugs such as azole antifungals (e.g. ketoconazole, itraconazole, miconazole and fluconazole) and macrolide antibacterials (e.g. erythromycin, clarithrod-mycin and troleandomycin), which can inhibit cisapride metabolism by interfering with the CYP3A4 isoenzyme.
authors.affiliation: Department of Internal Medicine and Therapeutics, Section of Experimental and Clinical Pharmacology, University of Pavia, Pavia, Italy. tonini@unipv.it
authors.forename: M
authors.initials: M
authors.lastname: Tonini
authors.forename: F
authors.initials: F
authors.lastname: De Ponti
authors.forename: A
authors.initials: A
authors.lastname: Di Nucci
authors.forename: F
authors.initials: F
authors.lastname: Crema
mesh_terms: D001549:Benzamides / Q000009:adverse effects*; D020117:Cisapride / Q000009:adverse effects; D002986:Clinical Trials as Topic; D018492:Dopamine Antagonists / Q000009:adverse effects*; D005544:Forecasting; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006321:Heart / Q000187:drug effects*; D006801:Humans
chemical_list: D001549:Benzamides; D018492:Dopamine Antagonists; D005765:Gastrointestinal Agents; D020117:Cisapride